ATE469886T1 - 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen - Google Patents

17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen

Info

Publication number
ATE469886T1
ATE469886T1 AT03783382T AT03783382T ATE469886T1 AT E469886 T1 ATE469886 T1 AT E469886T1 AT 03783382 T AT03783382 T AT 03783382T AT 03783382 T AT03783382 T AT 03783382T AT E469886 T1 ATE469886 T1 AT E469886T1
Authority
AT
Austria
Prior art keywords
17beta
inhibitor
treatment
hydroxysteroid dehydrogenase
dependent diseases
Prior art date
Application number
AT03783382T
Other languages
German (de)
English (en)
Inventor
Kamil Paruch
Timothy Guzi
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE469886T1 publication Critical patent/ATE469886T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
AT03783382T 2002-11-18 2003-11-14 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen ATE469886T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42726302P 2002-11-18 2002-11-18
PCT/US2003/036203 WO2004046111A1 (en) 2002-11-18 2003-11-14 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases

Publications (1)

Publication Number Publication Date
ATE469886T1 true ATE469886T1 (de) 2010-06-15

Family

ID=32326512

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03783382T ATE469886T1 (de) 2002-11-18 2003-11-14 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen

Country Status (16)

Country Link
US (2) US7074795B2 (enExample)
EP (1) EP1562901B1 (enExample)
JP (2) JP4614770B2 (enExample)
CN (1) CN100374421C (enExample)
AR (1) AR042046A1 (enExample)
AT (1) ATE469886T1 (enExample)
AU (1) AU2003290799A1 (enExample)
CA (1) CA2506290C (enExample)
CL (1) CL2003002356A1 (enExample)
DE (1) DE60332862D1 (enExample)
ES (1) ES2345146T3 (enExample)
MX (1) MXPA05005360A (enExample)
MY (1) MY130792A (enExample)
PE (1) PE20040750A1 (enExample)
TW (1) TW200412964A (enExample)
WO (1) WO2004046111A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003293555A1 (en) 2002-12-17 2004-07-29 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
WO2007016496A2 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
US8501940B2 (en) * 2008-07-15 2013-08-06 Hoffmann-La Roche Inc. Tetrahydrocinnoline derivatives
CN106890100A (zh) * 2011-04-25 2017-06-27 朴俊炯 用于预防脱发和促进毛发生长的局部施用的组合物
AU2014300894A1 (en) 2013-06-25 2016-01-28 Forendo Pharma Ltd Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase
TW201512215A (zh) 2013-06-25 2015-04-01 Forendo Pharma Ltd 治療活性雌三烯噻唑衍生物
JP6456373B2 (ja) 2013-06-25 2019-01-23 フォレンド ファーマ リミテッド １７β−ヒドロキシステロイドデヒドロゲナーゼ タイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
WO2016102775A1 (en) 2014-12-23 2016-06-30 Forendo Pharma Ltd PRODRUGS OF 17β-HSD1 -INHIBITORS
US10413557B2 (en) 2014-12-23 2019-09-17 Forendo Pharma Ltd. Prodrugs of 17.BETA.-HSD1-inhibitors
MA43940A (fr) 2015-09-02 2018-12-12 Glaxosmithkline Ip No 2 Ltd Dicarboxamide de pyridinone utilisé comme inhibiteur de bromodomaine
SG11201911776PA (en) 2017-06-08 2020-01-30 Forendo Pharma Ltd 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
EP3724178B1 (en) 2017-12-15 2024-05-01 Inthera Bioscience AG 1-(piperidinocarbonylmethyl)-2-oxopiperazine derivatives for treating cancer
CA3122049C (en) 2018-12-05 2023-10-17 Forendo Pharma Ltd Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1
US12611406B2 (en) 2020-06-19 2026-04-28 Inthera Bioscience AG Oxopiperazine derivatives for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3590389T1 (de) 1984-08-02 1986-08-28 Schering Corp., Kenilworth, N.J. Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer
PH30747A (en) 1989-03-10 1997-10-17 Endorech Inc Combination therapy for the treatment of estrogen sensitive disease.
DK0595796T3 (da) 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
CA2062973C (en) 1989-07-07 2003-09-23 Fernand Labrie Combination therapy for prophylaxsis and/or treatment of benign prostatic hyperplasia
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
CZ285893B6 (cs) 1993-05-17 1999-11-17 Endorecherche Inc. Antiandrogenní sloučenina, její prekursor a farmaceutický prostředek ji obsahující
US6124115A (en) 1995-09-22 2000-09-26 Endorecherche Inc. Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase
ES2229340T3 (es) * 1996-09-13 2005-04-16 Schering Corporation Compuestos triciclicos antitumorales, inhibidores de farnesil-proteina-tranferasa.
MXPA00008868A (es) * 1998-03-11 2003-04-25 Endorech Inc Inhibidores de dihidrogenasa de 17 -hidroxiesteroide y metodos para su uso.
MY141661A (en) * 2001-09-06 2010-05-31 Schering Corp 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
ES2347643T3 (es) * 2001-10-17 2010-11-03 Schering Corporation Piperin- y piperazinacetamidas como inhibidores de 17beta hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades dependientes de androgenos.

Also Published As

Publication number Publication date
PE20040750A1 (es) 2004-11-06
CA2506290C (en) 2012-04-24
US20040127503A1 (en) 2004-07-01
JP4614770B2 (ja) 2011-01-19
CN100374421C (zh) 2008-03-12
ES2345146T3 (es) 2010-09-16
EP1562901A1 (en) 2005-08-17
MXPA05005360A (es) 2005-08-03
CA2506290A1 (en) 2004-06-03
JP2006513169A (ja) 2006-04-20
JP2010138204A (ja) 2010-06-24
US7074795B2 (en) 2006-07-11
WO2004046111A1 (en) 2004-06-03
HK1073313A1 (en) 2005-09-30
US7476681B2 (en) 2009-01-13
CN1738800A (zh) 2006-02-22
DE60332862D1 (de) 2010-07-15
AU2003290799A1 (en) 2004-06-15
AR042046A1 (es) 2005-06-08
US20060148816A1 (en) 2006-07-06
CL2003002356A1 (es) 2005-02-11
EP1562901B1 (en) 2010-06-02
TW200412964A (en) 2004-08-01
MY130792A (en) 2007-07-31

Similar Documents

Publication Publication Date Title
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
ATE344253T1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE494279T1 (de) Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
ATE550338T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
DK1944322T3 (da) Behandling af TNFalfa-relaterede sygdomme
DE60322451D1 (de) 4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
DE60332862D1 (de) 17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
DE60236743D1 (de) Zur behandlung androgenabhängiger krankheiten
EP1651237A4 (en) METHODS OF TREATING DERMATOLOGICAL DISORDERS
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties